A LinkedIn post from Orasis Pharmaceuticals highlights the company’s participation in the #VSTheExchange meeting hosted by Vision Source. The post notes that the forum focused on education around presbyopia eye drops and credits optometrists Jade Coats and Bobby “Chip” Wood, Jr. with addressing misconceptions to support broader adoption of treatment options.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests Orasis is aligning closely with the optometry community and leveraging professional education to support awareness of presbyopia therapies. For investors, this emphasis on clinician engagement may indicate a strategy to drive future uptake of presbyopia treatments, potentially supporting longer term revenue opportunities if educational efforts translate into increased prescribing behavior.
By publicly acknowledging Vision Source’s 35th anniversary and naming specific practitioners, the post underscores relationship-building with a large network of eye care providers. Strengthening ties with influential practitioners and organized optometry could help Orasis enhance its competitive position in the presbyopia segment, particularly as multiple companies pursue pharmacologic solutions for near-vision correction.